Anixa Biosciences, Inc. (ANIX): VRIO Analysis [Mar-2026 Updated]

Is Anixa Biosciences, Inc. (ANIX) sitting on a goldmine of sustainable competitive advantage? This VRIO analysis distills whether their core resources are truly Valuable, Rare, Inimitable, and Organized to outperform the competition. Dive in below to see the definitive verdict on their strategic positioning and what it means for their future success.

Anixa Biosciences, Inc. (ANIX) - VRIO Analysis: 1. FSHR-Targeted CAR-T/CER-T Technology Platform

This platform, now officially named liraltagene autoleucel, represents Anixa Biosciences, Inc.'s primary shot at near-term differentiation in the crowded cell therapy space, especially against solid tumors like ovarian cancer. The key is whether the promising early safety data translates into durable efficacy as they push the dose higher.

Value: Novel Approach to Solid Tumors

The FSHR-Targeted CAR-T/CER-T technology offers a different mechanism than the standard CAR-T therapies, which often struggle with solid tumors. By targeting the Follicle Stimulating Hormone Receptor (FSHR), which research suggests is selectively expressed on ovarian cancer cells and tumor vasculature, it aims to overcome those limitations. The Phase 1 trial (NCT05316129) is designed to evaluate safety and identify the Maximum Tolerated Dose (MTD) in women with recurrent ovarian cancer who have already failed at least two prior therapies. The company is defintely pushing the envelope on dose escalation.

• Target: FSHR, expressed on ovarian cells and tumor vasculature.
• Differentiation: Uses natural ligand FSH binding, termed CER-T (chimeric endocrine receptor-T cell).
• Clinical Progress: Completed dosing of the fourth cohort as of September 2025.

Rarity: Unique Target and Mechanism

The specific focus on FSHR via a CER-T mechanism is quite rare compared to the industry's heavy focus on targets like CD19. This uniqueness provides a temporary market advantage, assuming the science holds up. The World Health Organization (WHO) approved the International Non-Proprietary Name (INN), liraltagene autoleucel, on November 17, 2025, which is a concrete step toward potential future commercialization and recognition.

Imitability: Strong Intellectual Property Protection

The difficulty in copying this lies in the underlying science and the legal protection. Anixa Biosciences holds an exclusive worldwide license from The Wistar Institute for this technology. Furthermore, the United States Patent and Trademark Office (USPTO) issued U.S. Patent Number 12,384,826, extending protection for core methods and compositions until 2045. This long runway makes direct imitation extremely difficult and costly for competitors.

Organization: Active Clinical Testing and Financial Strain

The organization is clearly structured around testing this asset, evidenced by the clinical trial progression. They successfully escalated the dose in the Phase 1 trial without observing any dose-limiting toxicities (DLTs) in the fourth cohort. Specifically, the fourth cohort received 3×10⁶ CAR-positive cells/kg, which is a 30-fold increase over the initial 1×10⁵ cells/kg dose. However, the financial structure shows the pressure this work puts on the balance sheet. For the quarter ending January 31, 2025, Anixa Biosciences reported no revenue and a net loss of $3.213 million, with cash and cash equivalents at only $1.053 million as of that date. If onboarding for the next cohort takes longer than expected, cash runway becomes a near-term risk.

Here’s the quick math on the dose escalation:

What this estimate hides is the absolute cash burn required to reach the next milestone; the consensus EPS forecast for FY Oct 2025 is -$0.35.

Competitive Advantage Scoring

Based on the current evidence, the platform shows strong potential for a sustained advantage, contingent on positive clinical outcomes.

The current advantage is Sustained Competitive Advantage, provided the safety profile continues to hold at the higher planned dose of approximately 1×10⁷ cells/kg and efficacy signals are confirmed.

• Action: Finance needs to draft a 13-week cash view by Friday to model funding needs through the planned fifth cohort.

Anixa Biosciences, Inc. (ANIX) - VRIO Analysis: 2. $\alpha$-Lactalbumin Breast Cancer Vaccine Technology

Value: Addresses a massive market need by targeting $\alpha$-lactalbumin, offering potential for prevention and therapy in breast cancer.

The therapeutic breast cancer market is projected to reach $89.67 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 12.9%.

Rarity: Targeting a lactation-associated protein for cancer prevention is a distinct approach in the vaccine space.

The vaccine targets $\alpha$-lactalbumin, a protein typically expressed only in breast tissue during lactation, which re-emerges in many forms of breast cancer.

Imitability: Moderate; while the concept is novel, the underlying science is shared with collaborators.

The technology was invented at Cleveland Clinic, which is entitled to royalties and other commercialization revenues related to the technology.

Organization: Strong; Phase 1 is complete, immune responses were seen in over 70% of patients, and the IND transfer for Phase 2 is underway.

The Phase 1 clinical trial (NCT04674306) involved 35 total participants across three distinct cohorts.

Financial and Operational Metrics:

• Market Capitalization (as of Nov 5, 2025): $130.68 million.
• Stock Price Return (Past Six Months): 41.28%.
• Stock Price Return (Year-to-Date): 71.12%.
• Revenue and TTM Sales: zero.
• Earnings Per Share (EPS): -0.35.
• Current Ratio: 8.45.
• Debt-to-Equity Ratio: 0.01.
• Cash and Investments (End of FY 2024): $20 million.
• Cash Runway Claimed: Over 2.5 years.
• Chinese Patent Protection Expiration: 2040.

Competitive Advantage: Temporary, pending successful Phase 2 results and eventual regulatory approval.

The company has a US patent for the technology and a Chinese patent extending protection until 2040.

Anixa Biosciences, Inc. (ANIX) - VRIO Analysis: 3. Broad, Long-Term Intellectual Property Portfolio

Value: Provides a defensive moat around key technologies, crucial for attracting future partners or commercializing assets.

Rarity: Rare; having patents like the one extending CAR-T protection to 2045 is a significant long-term asset.

Imitability: Very high; patents are legally protected barriers to entry.

Organization: Excellent; the company actively secures and builds upon its IP, including a Chinese patent for the breast cancer vaccine.

Competitive Advantage: Sustained, as long as the patents remain valid and enforceable.

The intellectual property portfolio is characterized by long-term protection across core assets:

Specific components of the actively managed IP portfolio include:

• CAR-T technology protection secured through U.S. Patent Number 12,384,826, extending to 2045.
• Breast cancer vaccine technology, exclusively licensed from Cleveland Clinic, with U.S. Patent Number 12,472,205 set for issuance on November 18, 2025, extending protection into the mid-2040s.
• Chinese National Intellectual Property Administration Patent Number ZL2020800215666 for the breast cancer vaccine, extending protection into the 2040s.

Financial investment supporting IP development includes Research and development expenses reported at approximately \$1,552,000 for a recent quarter, up from \$1,349,000 in the prior year quarter. Total current assets as of January 31, 2025, were \$18,686,000.

Anixa Biosciences, Inc. (ANIX) - VRIO Analysis: 4. Strategic Clinical Development Partnership with Moffitt Cancer Center

Value: Provides access to world-leading expertise in cellular immunotherapy and a site for executing the complex CAR-T trial, evidenced by the trial's progression through dose escalation without dose-limiting toxicities (DLTs) up to $\mathbf{3 \times 106}$ CAR-positive cells per kilogram.

Rarity: Rare; access to top-tier, specialized clinical sites like Moffitt, a world leader in cancer immunotherapy treatments, is not easily replicated.

Imitability: High; these relationships are built on past performance, demonstrated by the trial moving to the planned fifth cohort, with a target dose of approximately $\mathbf{1 \times 107}$ cells/kg, pending safety review.

Organization: Strong; the partnership is effectively managing the dose escalation in the ovarian cancer trial (NCT05316129), evidenced by maintaining an incredibly low annual cash burn rate of about $\mathbf{\$5-7MM}$ by utilizing Moffitt's cell therapy facility investment.

Competitive Advantage: Sustained, as long as the relationship remains productive and mutually beneficial.

The operational progress of the Phase 1 clinical trial for the FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer under this partnership is summarized below:

Key operational and financial aspects managed through the Moffitt partnership include:

• The trial is being conducted under ClinicalTrials.gov identifier $\mathbf{NCT05316129}$.
• The trial is being run 'frugally' by taking advantage of Moffitt's investment in their cell therapy facility.
• The partnership has allowed Anixa to maintain an incredibly low annual cash burn rate of about $\mathbf{\$5-7MM}$.
• The study is being conducted under the direction of Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt.
• The fourth cohort dose of $\mathbf{3 \times 106}$ CAR-positive cells per kilogram represents a $\mathbf{30-fold}$ increase versus the first cohort dose of $\mathbf{1 \times 105}$ cells/kg.
• The therapy has shown no dose-limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity to date in the advanced cohorts.

Anixa Biosciences, Inc. (ANIX) - VRIO Analysis: 5. Exclusive Worldwide License for CAR-T Technology from The Wistar Institute

Value

Secures the foundational rights to the core CAR-T platform, which is essential for any future commercialization of that asset.

Rarity

Rare; exclusive rights to foundational, patented technology from a reputable institute are hard to obtain post-discovery.

Imitability

Very high; the license agreement itself is a legal barrier.

Organization

Good; the company is actively advancing the licensed technology through clinical trials.

• The CAR-T technology is being advanced through a Phase 1 clinical trial (NCT05316129) at Moffitt Cancer Center.
• The first patient in the trial was treated in August 2022.
• Patients in the fourth cohort are receiving a dose of three million CAR-positive cells per kilogram of body weight.
• This dose represents a 30-fold increase over the initial dose level.
• Research and development expenses incurred in fiscal year 2022 associated with CAR-T therapeutics were approximately $2,765,000.

Competitive Advantage

Sustained, contingent on meeting license obligations.

Anixa Biosciences, Inc. (ANIX) - VRIO Analysis: 6. Capital-Efficient Operating Model

Value: Extends the runway, meaning the company can advance multiple clinical programs without immediately needing large, dilutive funding rounds.

Rarity: Rare in the biotech sector; the average annual cash burn was only about $5–$6 million in recent years. The Cash Flow from Operating Activities for the fiscal year ending October 31, 2024, was $-7.33M USD.

Imitability: Moderate; it requires disciplined management, which is hard to maintain but not impossible for others to copy.

Organization: Excellent; management has demonstrably prioritized fiscal discipline, using only $7 million in cash during the 2024 fiscal year.

Competitive Advantage: Temporary, as management focus can shift, but currently a key differentiator against peers.

The capital efficiency is further evidenced by the quarterly operating cash flow figures:

• Cash flow from continuing operating activities for the quarter ending January 31, 2025: $-1.51M.
• Cash flow from continuing operating activities for the quarter ending April 30, 2024: $-1.5M.
• Cash flow from continuing operating activities for the quarter ending July 31, 2024: $-2.9M.
• Cash flow from continuing operating activities for the quarter ending October 31, 2024 (FY End): $-7.34M.

A detailed breakdown of recent operating cash flow is presented below:

Specific expense management highlights for the quarter ended January 31, 2025, compared to the prior year's same quarter include:

• Research and development expenses: Approximately $1,552,000.
• General and administrative expenses: $1,834,000, a decrease from $2,260,000 in the previous year.

The company reported Total Liabilities of $2,240K and Total Debt of $0 as of October 31, 2024.

Anixa Biosciences, Inc. (ANIX) - VRIO Analysis: 7. Pipeline of Multiple Cancer Vaccine Targets

The pipeline includes vaccines targeting breast, ovarian, lung, prostate, and colon cancers utilizing a unified technological approach. The breast cancer vaccine targets alpha-lactalbumin ($\alpha$LA), a protein re-emerging in many breast cancer forms. The ovarian cancer immunotherapy program utilizes Chimeric Endocrine Receptor-T cell (CER-T) technology targeting the follicle-stimulating hormone receptor (FSHR). The U.S. Department of Defense has provided funding for the Phase 1 breast cancer vaccine trial.

The breast cancer vaccine Phase 1 trial enrolled a total of 35 women across three distinct patient cohorts: 26 in the TNBC Group, 4 in the Prevention Group, and 5 in the Pembrolizumab Group. Preliminary findings from the Phase 1 trial showed that more than 70% of patients tested to date exhibited protocol-defined immune responses.

The breast cancer vaccine technology was invented at Cleveland Clinic and exclusively licensed to Anixa. Anixa Biosciences was awarded a key U.S. Patent expanding Breast Cancer Vaccine Intellectual Property protection into the 2040s. The company is actively planning a Phase 2 breast cancer vaccine trial in collaboration with Cleveland Clinic.

The company is advancing the breast cancer vaccine into Phase 2 development under its full sponsorship, following the initiation of the Investigational New Drug (IND) application transfer from Cleveland Clinic. The proposed Phase 2 trial is expected to commence in 2025 and last between two and three years.

The pipeline diversification includes the following vaccine/therapy targets:

• Breast Cancer Vaccine (Targeting $\alpha$LA)
• Ovarian Cancer Immunotherapy (CER-T targeting FSHR)
• Discovery program for Lung Cancer Vaccines
• Discovery program for Colon Cancer Vaccines
• Discovery program for Prostate Cancer Vaccines

Anixa Biosciences, Inc. (ANIX) - VRIO Analysis: 8. Regulatory Progress and WHO Naming for Lead Asset

Value: The World Health Organization (WHO) Expert Committee approved the International Non-Proprietary Name (INN) 'liraltagene autoleucel' for the lead CAR-T therapy targeting ovarian cancer on November 17, 2025. The shortened name for future communications is 'lira-cel'. This naming is a key step toward global recognition and potential future commercialization.

Rarity: The achievement of a WHO INN designation signals a relatively high level of regulatory maturity for a company at this development stage.

Imitability: This is a specific, achieved regulatory milestone, making the status of having the INN name difficult to imitate retrospectively.

Organization: Successful interaction with global health bodies like the WHO to secure the INN reflects effective organizational execution in regulatory affairs.

Competitive Advantage: The permanent association of the name 'liraltagene autoleucel' with the product provides a sustained marker of progress.

The lead asset is a CAR-T therapy targeting the follicle stimulating hormone receptor (FSHR). The therapy is currently being evaluated in a Phase 1 clinical trial under identifier NCT05316129, enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies. The technology is exclusively licensed to Anixa by The Wistar Institute.

Key statistical and financial context surrounding development-stage operations includes:

• The company's average annual cash burn has been approximately $5–6 million.
• As of the end of the 2024 fiscal year, Anixa reported $20 million in cash and investments, projecting over 2.5 years of cash runway.
• For the second fiscal quarter of 2024, the reported net loss was $3.1 million, which was below the projected loss of $3.5 million.
• As of January 29, 2025, the market capitalization was approximately $77,594,437.42.

The following table summarizes key data points related to the lead asset's development and regulatory environment:

For the company's breast cancer vaccine program, early Phase 1 data presented on November 8, 2024, indicated that over 70% of participants showed protocol-defined immune responses.

Anixa Biosciences, Inc. (ANIX) - VRIO Analysis: 9. Financial Position as of Early 2025

Value

The capital base provides funding capacity for ongoing trials without immediate revenue. Cash and short-term investments totaled approximately $19,924,000 as of October 31, 2024, calculated from $1,495,000 in Cash and cash equivalents and $18,429,000 in Short-term investments (derived from $18,653,000 in Result minus $224,000 difference in total current assets/components, or using the components explicitly stated in Result for Oct 31, 2024: Cash and cash equivalents: $1,271,000; Short-term investments: $18,653,000, totaling $19,924,000).

• Cash and cash equivalents (October 31, 2024): $1,271,000
• Short-term investments (October 31, 2024): $18,653,000

Rarity

Moderate; the cash position offers a buffer, with total current assets at $18,686,000 as of January 31, 2025. The company maintains a $0 debt level.

Imitability

Low; cash reserves are transient and directly dependent on financing activities. The company stated as of January 10, 2025, that existing cash, cash equivalents, and short-term investments were believed to be sufficient to fund activities for at least the next twelve months.

Organization

Good; management is demonstrating cost control, with operating costs decreasing from $3,609,000 in Q1 2024 to $3,386,000 in Q1 2025. Research and development expenses for Q1 2025 were approximately $1,552,000.

Competitive Advantage

Temporary; the cash position is being depleted by ongoing operational losses. The net loss for Q1 2025 was $3,213,000.

Finance

The company believes it has sufficient resources to operate for at least the next twelve months from the March 11, 2025 report date. A draft 13-week cash view is required by Friday.

Comparative Snapshot of Key Current Assets and Liabilities (in thousands):